N/A N=434 Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy
Allergic Rhinitis
Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=126 Herbal Treatment for Perennial Allergic Rhinitis
Perennial Allergic Rhinitis
Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score
Phase 3 N=1,992 The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis — -0.37; -0.44 Score on…
Phase 3 N=1,365 Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)
Perennial Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.39; -0.45; -0.36 Scores on a scale
Phase 3 N=716 Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)
Allergic Rhinitis
Primary: Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment — 9.63; 9.55; -3.76; -2.87 units on a scale — p=<.001
Phase 4 N=80 Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis
Non-allergic Rhinitis
Primary: Change in Visual Analogue Scale for Major Nasal Symptoms — 3.66; 4.29; 4.49; 5.6 score on a scale
N/A N=45 Nasal Allergen Challenge in Rhinitic Subjects
Asthma · Allergic Rhinitis
Primary: Change in Sputum Eosinophils Following Allergen Challenge — 5.6; 2.0; 6.0; 1.3 percentage of sputum eosinophils
Phase 2 N=78 A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis
Rhinitis, Allergic, Perennial and Seasonal
Primary: Weighted Mean of the Total Nasal Symptom Score (TNSS) (0-4) Hours (h) Post Start of Allergen Chamber Challenge on Day 8 — 5.190; 4.071; 3.840 Scores on a scale — p=<0.0001
Phase 2 N=30 The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study
Chronic Rhinitis
Primary: Change in Subjective Nasal Scoring — 0.62; 1.53 score on a scale — p=0.013
Phase 3 N=1,079 Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over First 2 Weeks of Treatment Period — -0.23; -0.33; -0.45 Scores on a scale
Phase 4 N=60 A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis
Rhinitis, Allergic, Perennial
Primary: Systolic Blood Pressure at Screening/Visit 1, Visit 2, and Visit 3 — 110.98; 110.63; 110.00 millimeters of mercury (mmHg) — p=>0.05
N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Phase 3 N=1,110 A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
Allergic Rhinitis · Perennial Allergic Rhinitis
Primary: Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS (rTNSS) Averaged Over the First 6 Weeks of Double-blind Treatment — -1.97; -1.82; -1.28 units on…
Phase 3 N=547 Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)
Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, Perennial
Primary: The Change From Baseline in the 12-hour AM/PM-PRIOR (Reflective) Total 5 Symptom Score (T5SS) From Subject Daily Diaries Averaged Over Treatment Days 1 to 15 — -3.01…
Phase 3 N=474 Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
Rhinitis, Allergic, Perennial
Primary: Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period — -2.5; -1.6 units on a scale — p=<0.001
Phase 2 N=70 Intranasal SB-705498 in Allergic Rhinitis (AR) Patients
Rhinitis
Primary: Mean Total Nasal Symptom Score (TNSS) and Its Individual Components on Day 8 — 6.53; 3.65; 6.57; 4.14 Score on scale
Phase 3 N=302 Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline (Day 1) Over the Entire Treatment Period in Daily, Reflective Total Nasal Symptom Scores (rTNSS) Over 6 Weeks — -2.69; -3.95 Scores on a scale…
Phase 3 N=1,214 Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment Period — -0.38; -0.47; -0.29 Scores on a scale
Phase 4 N=313 Singulair(R) In Asthma And Allergic Rhinitis (0476-383)
Asthma
Primary: Asthma Control — 312; 72; 0; 229 Participants
N/A N=10 Acupuncture for Nasal Congestion in Allergic Rhinitis
Allergic Rhinitis
Primary: Change in Visual Analog Scale (VAS) From Baseline to 6 Weeks (6-week Value Compared to Baseline Value) — -8; -2 Scale points
Phase 2 N=40 A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
Perennial Allergic Rhinoconjunctivitis · House Dust Mite Allergy
Primary: Conjunctival Provocation Test (CPT) With House Dust Mite Allergen Solutions. Change of Median Individual Allergen Tolerance Compared to Baseline (Factor of Increase in…
Phase 3 N=829 A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.32; -0.38; -0.47 Units on a Scale
Phase 3 N=907 Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.26; -0.48; -0.52; -0.58 Units on a Scale
Phase 3 N=333 Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)
Rhinitis, Allergic, Perennial
Primary: Change From Baseline in the Total Nasal Symptom Score at 2 Weeks — -3.9850; -1.9081 score on a scale — p=<0.0001
Phase 4 N=39 Allergic Rhinitis Changes the Sinus Microbiome
Seasonal Allergic Rhinitis
Primary: Total Nasal Symptom Score (TNSS) — 67.1; 78.0 score on a scale — p=0.391
N/A N=43 Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial
Vasomotor Rhinitis
Primary: Total Nasal Symptom Scores — 3.0; 3.1 score on a scale — p=0.45
Phase 3 N=351 A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)
Perennial Allergic Rhinitis
Primary: Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 Weeks — 7.84; 8.41; 8.27; 8.29 Units on a scale — p=0.0001
Phase 4 N=725 Study Of Allergic Rhinitis In Patients Who Also Have Asthma
Asthma
Primary: Mean Change From Baseline at Endpoint in Morning Peak Expiration Flow (PEF) for Intent-to-Treat Population — 26.4; 3.6 L/min — p=<0.001
Phase 3 N=80 A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)
Rhinitis, Allergic, Perennial
Primary: Number of Participants With Adverse Events and Adverse Drug Reactions — 76; 18 participants
Phase 4 N=62 ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)
Rhinitis, Allergic, Perennial
Primary: Mean Weekly Total 4 Symptom Score (T4SS) During the Treatment Period — 2.89; 3.15 units on a scale — p==0.667